Background: Sacral nerve neuromodulation (SNM) therapy has been successfully applied in adult patients with urinary and fecal incontinence. Recently, SNM therapy showed good results in adults with ...

Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral ...

The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...

Axonics Modulation Technologies has released topline clinical results from its ARTISAN-sacral neuromodulation (SNM) pivotal study. The Irvine, CA-based company’s Axonics r-SNM System was evaluated in ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. Over 10 months, complete continence was achieved by approximately half of implanted patients. Real-world ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...